Abstract Library

#4403 Ki-67 index cut-off values and survival prognostication in neuroendocrine neoplasms: Machine learning-based insights

Introduction: The current grading system for gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) is based on Ki-67 index and/or mitotic rate. By definition, high-grade NEN (neuroendocrine tumour grade 3 [NET G3] and neuroendocrine carcinoma [NEC]) have a Ki-67 >20%, while NET G1 have a Ki-67

Conference:

Presenting Author:

Authors: Melhorn P, Berchtold L, Mazal P, Raderer M, Kiesewetter B,

Keywords: neuroendocrine neoplasm, prognosis, ki-67 index,

#4078 Prostate-specific membrane antigen-targeting theranostics in neuroendocrine neoplasms – Initial results from the GI-PSMA phase II trial

Introduction: A single-center Phase II trial (“GI-PSMA”, NCT05547919) was conducted to evaluate prostate-specific membrane antigen (PSMA)-targeted theranostics in gastroenteropancreatic tumors.

Conference:

Presenting Author: Weich A

Authors: Weich A, Serfling S, Bayer J, Buck A, Bley T,

Keywords: neuroendocrine, PSMA-PET/CT, dosimetry, high-grade NEN, PSMA,

#3514 DLL3 expression and clinico-pathological data in 247 patients with NEN

Introduction: Delta-like protein 3 (DLL3) is currently under clinical investigation as a potential therapeutic target in small cell neuroendocrine lung cancer. Characterization of the levels and patterns of DLL3 expression in other neuroendocrine neoplasms (NEN) is limited.

Conference:

Presenting Author: Clausen M

Authors: Clausen M, Federspiel B, Carstensen F, Suppli M, Kjaer A,

Keywords: DLL3, high-grade NEN,

#3403 Trends in chemotherapy use in neuroendocrine neoplasms: One step beyond guidelines

Introduction: The therapeutic landscape of neuroendocrine neoplasms (NENs) is constantly evolving. Current guidelines reflect the complexity of treatment sequences and mainly incorporate evidence from phase 3 clinical trials. Chemotherapy (CT) is a valuable option for patients with lung, pancreatic, and high-grade NENs, but proper phase 3 randomized studies are an unmet need. Nevertheless, several phase 2 studies with CT have been presented and published in the last year, with impact in both clinical practice and guidelines.

Conference:

Presenting Author:

Authors: Hernando J, Garcia-Diaz H, Bellas Fernandez L, Garcia Alvarez A, Roca M,

Keywords: Chemotherapy, CAPTEM, GUIDELINES,

#3280 A patient derived organoid model of neuroendocrine neoplasms enables long-term growth in vitro of low grade tumors and reveals therapeutic vulnerabilities

Introduction: A paucity of in vitro and in vivo models has limited the study of neuroendocrine neoplasms (NENs).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Dayton T

Authors: Dayton T, Alcala N, Den Hartigh L, Moonen L, Levy S,

Keywords: organoids, growth factor dependencies, lung NETs,